Nogapendekin alfa inbakicept

Locations: 🇺🇸
OPN Healthcare INC, Glendale, California, United States
🇺🇸
OPN Healthcare INC/ Cancer and Blood Specialty Clinic, Los Alamitos, California, United States

A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Phase 2

Recruiting

Conditions: Platinum-resistant Ovarian Cancer

Interventions: Drug: Gemcitabine
Biological: N-803
Biological: M-CENK

First Posted Date: 2024-11-29

Last Posted Date: 2025-02-13

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 20

Registration Number: NCT06710288

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1

Recruiting

Conditions: Endometrial Cancer
Cancer of Endometrium
Carcinoma of Endometrium
Endometrial Carcinoma

Interventions: Biological: AdHER2DC vaccine
Biological: Pembrolizumab
Drug: Lenvatinib
Biological: N-803
Device: PATHWAY HER2 (4B5) assay

First Posted Date: 2024-02-12

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06253494

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PD-L1 T-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma
Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions: Biological: PD-L1 t-haNK
Drug: Cetuximab
Biological: N-803

First Posted Date: 2024-02-02

Last Posted Date: 2024-10-26

Lead Sponsor: Glenn J. Hanna

Target Recruit Count: 25

Registration Number: NCT06239220

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Stage IV Squamous Cell Carcinoma of the Head and Neck
Stage II Squamous Cell Carcinoma of the Head and Neck
Stage III Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: N-803
Drug: pembrolizumab
Biological: PD-L1 t-haNK cells

First Posted Date: 2023-12-08

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT06161545

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Retifanlimab
Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Drug: N-803
Drug: SX-682

First Posted Date: 2023-11-29

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06149481

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: Bevacizumab
Drug: PD-L1 t-haNK
Drug: N-803

First Posted Date: 2023-09-29

Last Posted Date: 2024-08-19

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 20

Registration Number: NCT06061809

Locations: 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Phase 1

Recruiting

Conditions: Healthy Subjects

Interventions: Drug: N-803

First Posted Date: 2023-09-18

Last Posted Date: 2024-01-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 10

Registration Number: NCT06040918

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1

Suspended

Conditions: Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Carcinomas
Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant
Biological: H1299 Cell Lysates
Drug: N-803
Device: Ventana PD-L1 (SP263 or SP142) assay

First Posted Date: 2022-12-08

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05642195

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy